NCT06976476 Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia Status RECRUITING Phase PHASE2
NCT06976437 A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors Status RECRUITING Phase EARLY_PHASE1
NCT06956170 All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT06953960 A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) Status RECRUITING Phase PHASE1/PHASE2
NCT06934044 A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma Status RECRUITING Phase PHASE1
NCT06933277 Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone for the Treatment of MM Patients Status RECRUITING Phase N/A
NCT06932562 A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant Status RECRUITING Phase PHASE3
NCT06931704 Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA) Status NOT_YET_RECRUITING Phase PHASE2
NCT06913192 Efficacy of Sequential BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplant-eligible Newly Diagnosed Multiple Myeloma Status NOT_YET_RECRUITING Phase PHASE1
NCT06913179 CAR-T Cell Therapy Combined With Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma Status NOT_YET_RECRUITING Phase PHASE1
NCT06910670 Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid Status RECRUITING Phase NA
NCT06910124 Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse Status RECRUITING Phase PHASE2
NCT06896916 Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Status RECRUITING Phase PHASE1
NCT06892522 A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations Status RECRUITING Phase PHASE1/PHASE2
NCT06876142 Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma Status SUSPENDED Phase PHASE1/PHASE2
NCT06871176 PET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Myeloma (MM) Status RECRUITING Phase NA
NCT06870760 Pre-malignant States to Hematologic Malignancies in Firefighters Status RECRUITING Phase N/A